SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.
Trial will evaluate IDE161, IDEAYA s investigational PARG inhibitor, in combination with KEYTRUDA® , Merck s anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential.
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today.